aTyr is a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways.
Our focus is on a newly discovered area of biology, the extracellular functionality of tRNA synthetases. Built on more than a decade of foundational science in this area, we have built a global intellectual property estate directed to all 20 human tRNA synthetases, with over 300 protein compositions patented.
Our lead clinical product candidate, ATYR1923, is a selective modulator of Neuropilin-2 (NRP2) that downregulates both the innate and adaptive immune responses in uncontrolled inflammatory disease states. We are developing ATYR1923 as a potential disease-modifying therapy for severe inflammatory lung diseases with high unmet medical need. This includes interstitial lung diseases (ILDs), a group of rare immune-mediated disorders that cause progressive fibrosis of the lung, and severe respiratory complications caused by COVID-19. We recently completed enrollment in a Phase 1b/2a clinical trial in pulmonary sarcoidosis, a major form of ILD. The study has been designed to evaluate the safety, tolerability, steroid sparing effect and immunogenicity of multiple doses of ATYR1923 and to evaluate established clinical endpoints and certain biomarkers to assess preliminary clinical activity of ATYR1923. The results of this study will guide future development of ATYR1923 in pulmonary sarcoidosis and provide insight for the potential of ATYR1923 in other ILDs such as chronic hypersensitivity pneumonitis (CHP) and connective tissue disease related ILD (CTD-ILD).
In response to the COVID-19 pandemic, we initiated and completed enrollment in a Phase 2 study of ATYR1923 in COVID-19 patients with severe respiratory complications. The study has been designed to evaluate the safety and preliminary efficacy of ATYR1923 as compared to placebo through the assessment of key clinical outcome measures.
As part of our preclinical program, we have initiated IND-enabling activities for ATYR2810, a fully humanized monoclonal antibody for the potential treatment of certain aggressive cancers where NRP2 is implicated. We are also advancing our preclinical pipeline of additional NRP2 targeting antibodies for cancer and inflammation and new tRNA synthetase candidates through internal research efforts, industry and academic collaborations.
H.C. Wainwright BioConnect 2021 ConferenceJan 11 - Jan 14, 2021
Phase 2 Topline Results for ATYR1923 in COVID-19 Conference CallJan 4, 2021 5:00 PM EST
aTyr Pharma Third Quarter 2020 Conference CallNov 12, 2020 5:00 PM EST